Jun 25, 9:55 AMENDRA Life Sciences signs definitive deal to merge subsidiary with ASP Isotopes’ Noble Africa, forming Noble Africa Inc. with holders owning about 3%
Index
-
P/E
-
EPS (ttm)
-8.15
Insider Own
46.89%
Shs Outstand
1.24M
Perf Week
4.83%
Market Cap
6.34M
Forward P/E
-
EPS next Y
-3.04
Insider Trans
0.00%
Shs Float
0.67M
Perf Month
-6.90%
Enterprise Value
6.44M
PEG
-
EPS next Q
-0.84
Inst Own
7.06%
Perf Quarter
8.71%
Income
-7.30M
P/S
-
EPS this Y
60.36%
Inst Trans
0.75%
Perf Half Y
-2.16%
Sales
0.00M
P/B
3.46
EPS next Y
14.12%
ROA
-220.99%
Perf YTD
10.15%
Book/sh
1.44
P/C
17.61
EPS next 5Y
-
ROE
-412.60%
52W High
11.96 -58.28%
Perf Year
42.57%
Cash/sh
0.28
P/FCF
-
EPS past 3/5Y
89.62% 79.05%
ROIC
-345.41%
52W Low
2.96 68.58%
Perf 3Y
-99.82%
Dividend Est.
-
EV/EBITDA
-
Sales past 3/5Y
- -
Gross Margin
-
Volatility
28.92% 14.14%
Perf 5Y
-99.99%
Dividend TTM
-
EV/Sales
-
EPS Y/Y TTM
98.32%
Oper. Margin
-
ATR (14)
0.72
Perf 10Y
-
Dividend Ex-Date
-
Quick Ratio
0.64
Sales Y/Y TTM
-
Profit Margin
-
RSI (14)
50.19
Dividend Gr. 3/5Y
- -
Current Ratio
0.64
EPS Q/Q
41.18%
SMA20
2.77%
Beta
-0.00
Payout
-
Debt/Eq
0.26
Sales Q/Q
-
SMA50
-2.01%
Rel Volume
5.58
Prev Close
4.30
Employees
11
LT Debt/Eq
0.18
SMA200
1.38%
Avg Volume
28.39K
Price
4.99
IPO
Jun 30, 2017
Option/Short
No / Yes
Trades
Volume
158,537
Change
16.05%
Jun-25-26 12:11PM
09:51AM
May-18-26 08:00AM
May-14-26 08:00AM
Mar-31-26 04:05PM
08:00AM Loading…
Mar-25-26 08:00AM
Mar-03-26 10:15AM
Feb-26-26 08:00AM
Dec-04-25 08:00AM
Nov-20-25 08:00AM
Nov-17-25 08:00AM
Nov-14-25 09:25AM
Oct-23-25 08:00AM
Oct-16-25 08:57AM
Oct-13-25 08:14AM
08:00AM Loading…
08:00AM
Aug-14-25 04:05PM
Jun-16-25 08:00AM
May-15-25 04:05PM
Mar-31-25 08:05AM
08:00AM
Jan-28-25 12:00PM
Nov-22-24 08:00AM
Nov-15-24 09:24AM
Nov-12-24 08:00AM
Nov-06-24 08:00AM
Oct-22-24 08:00AM
Aug-28-24 04:17PM
Aug-22-24 04:14PM
Aug-16-24 08:00AM
04:05PM Loading…
Aug-13-24 04:05PM
08:00AM
Aug-07-24 08:00AM
Jun-17-24 08:11AM
07:40AM
Jun-05-24 07:35AM
Jun-04-24 09:21AM
May-20-24 08:00AM
May-15-24 03:10AM
May-14-24 04:05PM
May-07-24 08:00AM
May-02-24 08:00AM
Apr-01-24 09:59AM
Mar-29-24 06:21AM
Mar-28-24 08:53PM
04:05PM
Mar-21-24 08:00AM
Feb-27-24 08:00AM
Feb-21-24 08:00AM
Feb-14-24 08:30AM
Nov-29-23 08:00AM
Nov-27-23 08:00AM
Nov-15-23 01:23PM
Nov-14-23 04:05PM
Nov-08-23 08:00AM
Nov-07-23 04:05PM
Nov-06-23 08:00AM
Sep-07-23 08:00AM
Aug-30-23 08:00AM
Aug-23-23 08:00AM
Aug-20-23 11:20AM
Aug-15-23 06:49AM
Aug-14-23 04:05PM
01:30PM
Aug-01-23 08:00AM
Jul-12-23 05:15PM
03:27PM
02:42PM
02:01PM
12:31PM
10:30AM
09:42AM
07:05AM
Jul-06-23 04:45PM
Jun-07-23 08:00AM
May-15-23 04:05PM
May-04-23 08:00AM
May-02-23 04:01PM
Apr-28-23 08:00AM
Mar-17-23 05:00AM
Mar-15-23 10:32AM
Mar-14-23 04:05PM
Mar-07-23 04:05PM
Dec-08-22 09:55AM
Dec-05-22 08:00AM
Nov-14-22 04:05PM
Nov-09-22 08:00AM
Oct-25-22 08:00AM
Oct-04-22 08:00AM
Sep-29-22 04:05PM
Sep-06-22 08:00AM
Aug-24-22 08:40AM
Aug-15-22 04:30PM
04:05PM
Aug-08-22 10:16AM
Aug-04-22 08:00AM
Aug-02-22 08:00AM
Aug-01-22 08:00AM
Jul-11-22 08:00AM
Jun-28-22 08:00AM
ENDRA Life Sciences, Inc. engages in the development of medical devices for accurate liver fat measurement for use in metabolic disease detection and GLP-1 drug eligibility and management. The company was founded on July 18, 2007 and is headquartered in Ann Arbor, MI.
CEO & ChairmanMr. Alexander Y. Tokman
CFO & SecretaryMr. Richard Jacroux
Co-FounderDr. Jonathan Behr Ph.D.
Head of OperationsMr. Scott Sober
Head of Regulatory & Clinical AffairsMr. Ziad Rouag J.D.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Anthony DiGiandomenicoBoard MemberJun 26 '26Proposed Sale6.0070,822425,000Jun 25 06:24 PM